Sector News

Illumina debuts next-gen sequencing test for COVID-19

June 11, 2020
Life sciences

Illumina received an emergency authorization from the FDA for its COVID-19 test designed to sequence the full genome of the novel coronavirus.

Using the company’s high-throughput NovaSeq 6000 hardware, the diagnostic COVIDSeq Test is capable of processing over 3,000 samples at once, taken from nasopharyngeal and oropharyngeal swabs. Results are provided within 24 hours.

“COVIDSeq leverages the performance of [next-generation sequencing] to help address the global need for diagnostic testing to fight the COVID-19 pandemic,” Illumina CEO Francis deSouza said in a statement.

“Beyond diagnostic testing, Illumina and a number of our customers are exploring NGS-based workflows to enable high-volume screening to support a return to work and school,” deSouza said.

The test targets and amplifies 98 different segments of the SARS-CoV-2 genome, which Illumina says gives the kit high accuracy and sensitivity. COVIDSeq will first be available to a limited number of sites before expanding over the summer, the company said.

In mid-March, Illumina partnered up with metagenomics company IDbyDNA to offer new workflows focused on the coronavirus and other infectious diseases—including a co-marketing agreement for the latter’s Explify platform, which runs on the sequencing giant’s hardware.

That includes a DNA-based diagnostic that can identify over 50,000 microorganisms and 3,000 pathogens in the clinic as well as potential resistance profiles to antimicrobial drugs.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach